Large-scale data from the EURAMOS-1 cohort confirms existing survival rates and prognostic factors in osteosarcoma.
In conclusion, data from >2000 patients registered to EURAMOS-1 demonstrated survival rates in concordance with institution- or group-level osteosarcoma trials. Further efforts are required to drive improvements for patients who can be identified to be at higher risk of adverse outcome. This trial reaffirms known prognostic factors, and owing to the large numbers of patients registered, it sheds light on some additional factors to consider.
Smeland et al. (Sun,) studied this question.